Your report on tuberculosis (TB) vaccines perpetuates a flawed but widely held view. In fact, the lack of efficacy of the MVA85A vaccine in a recent human clinical trial was no surprise (Nature 502, S8-S9; 2013).
The trial followed an immunization regime previously used in four animal models in the past ten years. Careful examination of those results reveals that MVA85A offered no statistically significant increase in protection over the BCG (Bacillus Calmette-Guérin) vaccine alone in mice, guinea pigs, cows and non-human primates (see, for example, F. A. W. Verreck et al. PLoS ONE 4, e5264; 2009 , and S. A. Sharpe et al. Clin. Vaccine Immunol. 17, 1170 -1182 2010) .
The only exception is a mouse study (N. P. Goonetilleke et al. J. Immunol. 171, 1602 -1609 2003) , which is not comparable because a different immunization route was used (see C. N. Horvath and Z. Xing Adv. Exp. Med. Biol. 783, 267-278; 2013 By contrast, the world's leading universities do not expect their professors to teach for more than 200-400 hours a year, allowing them enough time for research. They also protect the intellectual property that results from this research, which contributes substantially to university budgets -amounting in some US universities to several billions of dollars a year (roughly the combined research budget for some provinces and republics in the Russian Federation).
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